Effect of bromocriptine in diabetes treatment

The efficacy of bromocriptine for glycemic control in poorly controlled type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201204156710N3

Enrollment

Registered

2012-05-28

Start date

2012-05-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

We start medication with low dose of bromocriptine (1.25 milligram) in bedtime. And, 1.25 milligram of the drug will be added every 3 days (in cases of no complication). We continue this until we reac

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All type 2 diabetes patients who do not have exclusion criteria. Exclusion criteria: 1- Age lower than 30 and more than 65; 2- HbA1C lower than 7.5% and more than 9%; 3- Patients who are not willing to participate; 4- Pregnant patients and lactating patients; 5- Syncope attacks; 6- Severe psychosis; 7- Sensitive to bromocriptine and ergot drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood sugar. Timepoint: 1.5 months. Method of measurement: lab tests.	—

Secondary

Measure	Time frame
Lipid profile. Timepoint: 3 and 6 months. Method of measurement: lab tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Nooshin Milanchian

Medical faculty of Tabriz University of medical sciences

noomilan@yahoo.com+98 41 1335 7850

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026